Treatment Resistant Depression

Neurology
19
Pipeline Programs
9
Companies
18
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
13
0
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
KetaminePhase 41 trial
Active Trials
NCT02772211Unknown60Est. Jan 2017
Compass Pathways
Compass PathwaysUK - Cheshire
8 programs
5
2
PsilocybinPhase 3
PsilocybinPhase 3
PsilocybinPhase 2
PsilocybinPhase 2
PsilocybinPhase 2
+3 more programs
Compass Therapeutics
8 programs
5
2
PsilocybinPhase 31 trial
PsilocybinPhase 31 trial
PsilocybinPhase 21 trial
PsilocybinPhase 21 trial
PsilocybinPhase 21 trial
+3 more programs
Active Trials
NCT04519957Completed66Est. Aug 2022
NCT04433858Active Not RecruitingEst. May 2026
NCT04433845UnknownEst. Apr 2023
+5 more trials
Axsome Therapeutics
Axsome TherapeuticsNY - New York
2 programs
2
AXS-05Phase 21 trial
AXS-05Phase 21 trial
Active Trials
NCT04634669Terminated181Est. Mar 2022
NCT04608396Completed44Est. Jul 2021
Precision BioSciences
1 program
1
PCN-101Phase 21 trial
Active Trials
NCT05414422Completed102Est. Nov 2022
GH Research
GH ResearchDUBLIN 2, Ireland
1 program
1
5 Methoxy N,N DimethyltryptaminePhase 1/21 trial
Active Trials
NCT04698603CompletedEst. Nov 2021
Abbott
AbbottABBOTT PARK, IL
2 programs
Libra Deep Brain Stimulation SystemN/A1 trial
Sham-stimulationN/A1 trial
Active Trials
NCT01801319Unknown40Est. Dec 2017
NCT06423430Recruiting100Est. Apr 2029
Soterix Medical
Soterix MedicalNJ - Woodbridge
2 programs
Neuro-navigated Transcranial Magnetic StimulationN/A1 trial
Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT04956081CompletedEst. Sep 2025
NCT05598931CompletedEst. Oct 2024
Alliance Pharmaceuticals
1 program
Synergy, Epidural cortical stimulationN/A1 trial
Active Trials
NCT00565617Active Not Recruiting5Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
TevaKetamine
Compass TherapeuticsPsilocybin
Compass TherapeuticsPsilocybin
Compass TherapeuticsPsilocybin
Precision BioSciencesPCN-101
Compass TherapeuticsPsilocybin
Compass TherapeuticsPsilocybin
Axsome TherapeuticsAXS-05
Axsome TherapeuticsAXS-05
Compass TherapeuticsPsilocybin
Compass TherapeuticsPsilocybin
GH Research5 Methoxy N,N Dimethyltryptamine
AbbottSham-stimulation
Soterix MedicalNeuro-navigated Transcranial Magnetic Stimulation
Soterix MedicalTranscranial Magnetic Stimulation

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 1,677 patients across 18 trials

NCT02772211TevaKetamine

D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression

Start: Jun 2016Est. completion: Jan 201760 patients
Phase 4Unknown
NCT05711940Compass TherapeuticsPsilocybin

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Start: Feb 2023Est. completion: Dec 2026572 patients
Phase 3Active Not Recruiting
NCT05624268Compass TherapeuticsPsilocybin

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Start: Jan 2023Est. completion: Apr 2026255 patients
Phase 3Active Not Recruiting
NCT05220410Compass TherapeuticsPsilocybin

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Start: Mar 2022Est. completion: May 2025
Phase 2Completed
NCT05414422Precision BioSciencesPCN-101

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Start: Feb 2022Est. completion: Nov 2022102 patients
Phase 2Completed
NCT04433858Compass TherapeuticsPsilocybin

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Start: Mar 2021Est. completion: May 2026
Phase 2Active Not Recruiting
NCT04433845Compass TherapeuticsPsilocybin

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Start: Mar 2021Est. completion: Apr 2023
Phase 2Unknown
NCT04634669Axsome TherapeuticsAXS-05

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Start: Sep 2020Est. completion: Mar 2022181 patients
Phase 2Terminated
NCT04608396Axsome TherapeuticsAXS-05

Mechanistic Evaluation of Response in TRD (MERIT)

Start: Aug 2020Est. completion: Jul 202144 patients
Phase 2Completed
NCT04739865Compass TherapeuticsPsilocybin

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Start: Aug 2020Est. completion: Oct 202119 patients
Phase 2Completed
NCT03775200Compass TherapeuticsPsilocybin

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Start: Mar 2019Est. completion: Sep 2021233 patients
Phase 2Completed
NCT04698603GH Research5 Methoxy N,N Dimethyltryptamine

Clinical Study of GH001 in Depression

Start: Nov 2019Est. completion: Nov 2021
Phase 1/2Completed
NCT06423430AbbottSham-stimulation

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Start: Sep 2024Est. completion: Apr 2029100 patients
N/ARecruiting
NCT04956081Soterix MedicalNeuro-navigated Transcranial Magnetic Stimulation

Virtual Neuro-Navigation System for Personalized Community Based TMS

Start: Jul 2021Est. completion: Sep 2025
N/ACompleted
NCT05598931Soterix MedicalTranscranial Magnetic Stimulation

Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

Start: Jul 2021Est. completion: Oct 2024
N/ACompleted
NCT04519957Compass TherapeuticsLong Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

Start: Jul 2020Est. completion: Aug 202266 patients
N/ACompleted
NCT01801319AbbottLibra Deep Brain Stimulation System

A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression

Start: Jun 2011Est. completion: Dec 201740 patients
N/AUnknown
NCT00565617Alliance PharmaceuticalsSynergy, Epidural cortical stimulation

Epidural Cortical Stimulation for Depression

Start: Oct 2007Est. completion: Dec 20285 patients
N/AActive Not Recruiting

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
4h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
4h ago

Director of Medical Affairs

CoMind
Miami, FL
4h ago

Director of Finance

CoMind
London, UK
4h ago

Electronics Engineering Manager

CoMind
London, UK
4h ago

Director of Information Technology

Zavation Medical Products
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,677 patients
9 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)